Drug Trial Radar · NCT05650879
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Mar 20, 2023
Primary completion
Jul 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Enliven TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.
Conditions
- HER2 Mutant Non-small Cell Lung Cancer
- HER2-positive Metastatic Breast Cancer
- HER2 Gene Mutation
- HER2 Amplification
Interventions
ELVN-002Drug
capsule
Fam-Trastuzumab Deruxtecan-NxkiDrug
intravenous
Trastuzumab emtansineDrug
intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities in Phase 1a monotherapyTime frame: 21 days
- Incidence of adverse events in Phase 1a monotherapyTime frame: 24 months
- incidence of laboratory abnormalities in Phase 1a monotherapyTime frame: 24 months
- incidence of ECG abnormalities in Phase 1a monotherapyTime frame: 24 months
- incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd)Time frame: 42 days
- Incidence of adverse events in Phase 1a combination with T-DXdTime frame: 24 months
- incidence of laboratory abnormalities in Phase 1a combination with T-DXdTime frame: 24 months
- incidence of ECG abnormalities in Phase 1a combination with T-DXdTime frame: 24 months
- incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1)Time frame: 42 days
- Incidence of adverse events in Phase 1a combination with T-DM1Time frame: 24 months
- incidence of laboratory abnormalities in Phase 1a combination with T-DM1Time frame: 24 months
- incidence of ECG abnormalities in Phase 1a combination with T-DM1Time frame: 24 months
- Incidence of adverse events in Phase 1b monotherapyTime frame: 24 months
- incidence of laboratory abnormalities in Phase 1b monotherapyTime frame: 24 months
- incidence of ECG abnormalities in Phase 1b monotherapyTime frame: 24 months
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
University of Colorado - Anschutz Medical Campus - PPDS
Aurora, Colorado
Advent Health Orlando
Orlando, Florida
BRCR Medical Center Inc
Plantation, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
NEXT/Virginia Cancer Specialists
Fairfax, Virginia
Blacktown Hospital
Darlinghurst, Australia
Macquarie University Hospital
Westmead, New South Wales, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
Centre Georges François Leclerc
Dijon, France
Centre Léon Berard
Lyon, France
Institut Gustave Roussy (IGR)
Villejuif, France
Hôpital de la Timone Centre d'essais en cancérologie de Marseille (CEPCM-CLIPP)
Marseille, Bouches-du-Rhône, France
Hôpital Pontchaillou
Rennes, Brittany Region, France
Centre Francois Baclesse
Caen, Calvados, France
EDOG - Institut Bergonie - PPDS
Bordeaux, Gironde, France
Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
Unità Operativa Oncologia medica ed Ematologia
Rozzano, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
Fondazione del Piemonte per l'Oncologia (IRCCS)
Candiolo, Piedmont, Italy
SOC Oncologia Medica e dei Tumori lmmunocorrelati, Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS
Aviano, Pordenone, Italy
Azienda Ospedaliero Universitaria delle Marche
Ancona, The Marches, Italy
Gachon University Gil Medical Center
Incheon, South Korea
Severence Hospital, Yonsei University
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggido, South Korea
START Barcelona Hospital HM Nou Delfos
Barcelona, Spain
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
lnstitut Catala d'Oncologia (ICO) L'Hospitalet, Servicio de Oncologia Medica
L'Hospitalet de Llobregat, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Lleida, Spain
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
Taichung Veterans General Hospital
Taichung, Taiwan
National Chen Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.